Get the Stockscreener App
28.92
4.12%
1.166
Oculis Holding Ag stock is traded at $28.92, with a volume of 85,763.
It is up +4.12% in the last 24 hours and up +9.70% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
See More
Previous Close:
$27.75
Open:
$27.98
24h Volume:
85,763
Relative Volume:
0.25
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
$-118.12M
P/E Ratio:
-12.68
EPS:
-2.2802
Net Cash Flow:
$-82.63M
1W Performance:
+9.24%
1M Performance:
+9.70%
6M Performance:
+48.86%
1Y Performance:
+57.80%
1-Day Range:
$27.98
$29.46
1-Week Range:
$26.43
$29.46
52-Week Range:
$16.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
28.93 | 1.61B | 0 | -118.12M | -82.63M | -2.2802 |
VRTX
Vertex Pharmaceuticals Inc
|
424.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.83 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.79 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.83 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
60% go untreated in DME; Oculis nears June eye-drop data - Stock Titan
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting - GlobeNewswire
Oculis Nears Key Milestone as Phase 3 OCS-01 Eye Drop Trial in Diabetic Macular Edema Completes - TipRanks
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com
Gildi lifeyrissjodur Makes New Investment in Oculis Holding AG $OCS - MarketBeat
Oculis Highlights Innovative Late-Stage Pipeline and Unmet Needs in Diabetic Macular Edema at ARVO 2026 - Quiver Quantitative
June eye-drop data nears as Oculis brings DME, optic neuritis studies - Stock Titan
OCSAW Price History for Oculis Holding Ag Warrants Stock - Barchart
Oculis (NASDAQ:OCS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
OCSAW Chart for Oculis Holding Ag Warrants Stock - Barchart.com
LSP 7 holds 6.95M shares in Oculis Holding (OCS) as of Mar 31, 2026 - Stock Titan
Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? - Yahoo Finance
Oculis reports final phase 3 patient visit for DME eye drops - Eyes On Eyecare
Assessing Oculis Holding (OCS) Valuation As DIAMOND Phase 3 Trials Reach Key Completion Milestone - simplywall.st
Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing - TipRanks
(OCS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session - TipRanks
Oculis (Nasdaq: OCS) sets 2026 AGM, details late-stage pipeline and expanded share capital tools - Stock Titan
Oculis Publishes Invitation to the Annual General Meeting - GlobeNewswire
Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright reiterates Oculis stock rating on trial completion By Investing.com - Investing.com Australia
Why Oculis Holding (OCS) Is Up 5.5% After Phase 3 DME Trial Milestone – And What's Next - simplywall.st
OCS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $44 - GuruFocus
Oculis completes final patient visit in OCS-01 phase 3 trial in DME - Ophthalmology Times
HC Wainwright Reiterates Buy Rating for Oculis (NASDAQ:OCS) - MarketBeat
Oculis Holding AG Announces Completion of Last Patient Visit in Phase 3 Diamond Program with OCS-01 Eye Drops for Treatment of Diabetic Macular Edema - marketscreener.com
Oculis Completes Last Patient Visits in Phase 3 DIAMOND Trials for OCS-01, Anticipates Topline Results in June 2026 - Quiver Quantitative
800+ patients finish Oculis diabetic eye-drop trials before June data - Stock Titan
Oculis Announces Completion of Last Patient Visit in Phase - GlobeNewswire
Oculis Holding AG (OCS) Stock Analysis: A Promising Biotech with a 74.79% Potential Upside - DirectorsTalk Interviews
Liquidity Mapping Around (OCS) Price Events - Stock Traders Daily
Tech Rally: Will Oculis Holding AG Equity Warrant benefit from green energy policiesMarket Sentiment Summary & Risk Managed Investment Signals - baoquankhu1.vn
Surprises Report: Is Oculis Holding AG Equity Warrant exposed to political riskPortfolio Risk Summary & Proven Capital Preservation Methods - baoquankhu1.vn
Is Oculis (OCSAW) Stock heavily shorted | Price at $15.99, Up 0.60%Global Trading Community - Cổng thông tin điện tử tỉnh Lào Cai
OCS Options Volatility — NASDAQ:OCS - TradingView
OCS Options Chain — NASDAQ:OCS - TradingView
Value Recap: Will Oculis Holding AG Equity Warrant benefit from green energy policiesWeekly Profit Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Fund Flows: Whats next for Oculis Holding AG stockShare Buyback & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Can Oculis (OCS) Stock Recover Now | Price at $27.39, Up 0.74%RSI Oversold Stocks - Cổng thông tin điện tử tỉnh Lào Cai
OCS Stock Price, Quote & Chart | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Director Riad Sherif's Oculis RSUs vested and settled on April 5 - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Will Oculis (OCS) Stock Go Higher | Price at $27.00, Up 2.27%Buy Zone Stocks - Xã Thanh Hà
Oculis Holding AG (OCSAW) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces 2026 Investor Conference Participation and Key Updates - Intellectia AI
Oculis to Participate in Upcoming Investor Conferences - Bitget
Oculis Holding AG Announces Upcoming Investor Conferences and Pipeline Updates for 2026 Progress - Quiver Quantitative
Investment Report: Can Oculis Holding AG Equity Warrant stock double in the next yearPortfolio Risk Summary & Capital Efficient Trade Techniques - baoquankhu1.vn
Assessing Oculis Holding (OCS) Valuation After EMA PRIME Designation For Privosegtor - Sahm
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate - Sahm
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.78%
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):